Strategic funding OpiAID has secured multiple grants and federal funding (SBIR $2.8M, early federal grant $276K) and has repeatedly been recognized with grants and awards, indicating strong validation by government and industry, suggesting growth opportunities with government, healthcare networks, and research-heavy clients.

Clinical impact The company focuses on decision support for clinicians to improve patient retention in Medically Assisted Treatment for opioid use disorder, highlighting a clear value proposition to treatment centers, MAT programs, and payer networks seeking better outcomes and reduced costs.

Recognition momentum Consistent awards and finalist placements since 2020 (Best AI/Data Analytics in NC, Top Startups to Watch, Venture Challenge finalists) signal credibility and a compelling story for partnerships, co-selling with healthcare tech players, and investor interest.

Moderate scale, high potential With 11-50 employees and revenue in the 1M–10M range, OpiAID is a nimble player positioned to partner with mid-market clinics, regional health networks, and specialty addiction treatment providers seeking scalable AI-enabled solutions.

Tech and data focus Tech stack emphasizes web and data delivery capabilities (Open Graph, RSS, WordPress ecosystem) paired with ML/decision support for clinical use, creating opportunities to integrate with EHRs, clinic websites, and payer portals for a seamless customer experience.